Silexion Therapeutics Corp (SLXN) Form 10-Q — Aug 14, 2026
Silexion Therapeutics' 10-Q discloses substantial doubt about its ability to continue as a going concern, with just $2.2 million in cash at June 30, 2026 — enough only through Q4 2026 under its current plan — against a $6.3 million first-half net loss and $6.6 million of negative operating cash flow. Shareholders' equity stood at only $44,000 at quarter-end, far below the $2.5 million Nasdaq minimum, though the company says its August 2026 offering ($2.5 million gross at $0.65 per share), $0.3 million of ATM sales, and $0.8 million of sponsor note conversions lifted pro forma equity to roughly $3.2 million.
Key figures
- Cash Position
- 2229000
- Shares Outstanding
- 5560256
- Cash runway
- through Q4 2026 under current business plan
- Reverse splits
- ["1-for-10 (May 28, 2026)","1-for-15 (July 28, 2025)","1-for-9 (November 27, 2024)"]
- Atm total capacity
- 13170000
- Accumulated deficit
- 61450000
- Ga expenses h1 2026
- 2847000
- Rd expenses h1 2026
- 3582000
- Atm q2 2026 avg price
- 13.4
- Rd expense growth pct
- 125
- Atm capacity remaining
- 10900000
- Atm jul aug 2026 avg price
- 2.1
- Shareholders equity jun30 2026
- 44000
- Sponsor note original principal
- 3433000
- Warrants outstanding jun30 2026
- 523344
- August 2026 offering net proceeds
- 2100000
- May 2026 inducement gross proceeds
- 998000
- August 2026 offering gross proceeds
- 2500000
- Share count growth since dec31 2025
- 17.8x (312,665 to 5,560,256)
- Sponsor note outstanding jun30 2026
- 1037000
- August 2026 offering price per share
- 0.65
- Shareholders equity pro forma aug2026
- 3200000
Price after filing
Close on the filing date to close N calendar days later (from $0.42). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.